This report

◆ analyzes the status, competition pattern and development direction of the insulin industry

◆ Focuses on the operation and development prospect of three foreign insulin producers including Novo Nordisk, Eli Lilly and Sanofi-Aventis as well as several large-scale domestic insulin producers, such as Jilin Tonghua Dongbao, Beijing Gan & Lee Pharmaceutical, and Jiangsu Wanbang Biopharmaceuticals

Please visit our website to order this report and find more information about other titles at www.researchinchina.com

Related Products

<table>
<thead>
<tr>
<th>Related Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>China Medical Imaging Device Industry Report, 2010</td>
</tr>
<tr>
<td>China Medical Monitor Industry Report, 2010</td>
</tr>
<tr>
<td>China Hospital Industry Development and Investment Report, 2009-2010</td>
</tr>
<tr>
<td>China Heparin Industry Report, 2010</td>
</tr>
<tr>
<td>China Hemodialysis Industry Report, 2009-2010</td>
</tr>
<tr>
<td>China Diagnostic Reagent Industry Report, 2010</td>
</tr>
</tbody>
</table>
Abstract

In 2009, China’s insulin market size reached up to RMB5.3 billion, but still accounted for less than 6% of the global market. China has the world’s most diabetes patients, which is 92 million at present. In addition, the overall treatment rate of Chinese diabetes patients is less than 30%, and the per capita consumption of insulin is low, which is only about 0.8% of that of American patients. Therefore, China’s insulin market has great potential.

The insulin industry is a high-tech industry. China’s genetically engineered human insulin is still in the initial stage of industrialization, and has weak global competitiveness due to its high production cost and small production scale, which has led to the monopoly of imported insulin in China. In the first three quarters of 2010, Novo Nordisk, Eli Lilly and Sanofi-Aventis accounted for 90.6% of China’s insulin market, while Tonghua Dongbao, the largest domestic company, only accounted for 3.7%. In addition, more and more enterprises are entering the Chinese insulin market, such as The United Laboratories of Hong Kong and Bayer of Germany.

Enterprises in China’s Insulin Market by Market Share, Jan.-Sep.2010

Source: IMS, ResearchInChina

The report not only analyzes the status quo, competition pattern and development direction of the insulin industry as a whole and its market segments, but also makes a detailed analysis of the operation and development prospect of three foreign insulin producers including Novo Nordisk, Eli Lilly and Sanofi-Aventis as well as several large-scale domestic insulin producers.
Novo Nordisk of Denmark is an insulin industry leader in both China and the world; it accounted for 83.4% of China’s recombinant human insulin market and 52.2% of China’s insulin analog market in 2008.

Eli Lilly of the United States is the second pharmaceutical giant entering in China’s insulin market. It accounted for 12.3% of China’s recombinant human insulin market and 7.7% of China’s insulin analog market in 2008; it is expanding its presence in China. It invested over USD40 million in an insulin expansion project in Suzhou in 2009.

Sanofi-Aventis of France is the world’s first producer of insulin glargine analog, and accounted for 36.1% of China’s insulin analog market in 2008.

Jilin Tonghua Dongbao is China’s largest producer of recombinant human insulin; in 2010, its insulin API capacity was 3,000 kg and the insulin dosage form capacity was 70 million bottles in 2010.

Beijing Gan & Lee Pharmaceutical is a company controlled by Tonghua Dongbao. Gan & Lee and Sanofi Aventis are the world’s only two insulin glargine analog manufacturers.

Jiangsu Wanbang Biopharmaceuticals is a leading animal insulin enterprise in China, and occupied more than 80% of China’s animal insulin market in 2009. In addition, its animal insulin has been selected into the national catalog of essential drugs.
1. Overview of Insulin Industry
   1.1 Definition & Classification
   1.2 Industry Chain

2. International Environment for the Operation China’s Insulin Market
   2.1 Current Development
      2.1.1 Market Size
      2.1.2 R&D Direction of New Drugs
      2.1.3 Production Process
   2.2 Market Supply and Demand
   2.3 Competition Pattern
   2.4 Development Prospect
      2.4.1 Increasingly Serious Diabetes Problem
      2.4.2 Competitive Drugs or Alternative Therapies
      2.4.3 Market Forecast

3. Status Quo & Prospect of China’s Insulin Market
   3.1 Market Status
   3.2 Market Supply & Demand
   3.3 Competition Pattern
      3.3.1 Foreign Monopoly
      3.3.2 Newcomers
   3.4 Industry Gross Margin and Price
   3.5 Policy Environment
   3.6 Development Prospect
      3.6.1 Per Capita Consumption of Insulin will Increase
      3.6.2 Market Share of Insulin will Increase

4. Import and Export of China’s Insulin Market
   4.1 Import & Export of Insulin and its Salts
      4.1.1 Export
      4.1.2 Import
   4.2 Import & Export of Insulin-containing Drugs in Unfinished Dosage Form
   4.3 Import & Export of Insulin-containing Drugs in Finished Dosage Form
      4.3.1 Export
      4.3.2 Import

5. Advantageous Enterprises in China’s Insulin Production Industry
   5.1 Tonghua Dongbao
      5.1.1 Profile
      5.1.2 Operation
      5.1.3 Marketing Strategy
      5.1.4 Development Trend
      5.1.5 Gan & Lee Pharmaceutical
   5.2 Novo Nordisk
      5.2.1 Profile
      5.2.2 Operation
      5.2.3 Operation in China
      5.2.4 Development Trend
   5.3 Eli Lilly
      5.3.1 Profile
      5.3.2 Operation
      5.3.3 Operation in China
      5.3.4 Development Trend
   5.4 Sanofi-Aventis
      5.4.1 Profile
      5.4.2 Operation
      5.4.3 Operation in China
      5.4.4 Development Trend
   5.5 Wanbang Biopharmaceuticals
      5.5.1 Profile
      5.5.2 Operation
      5.5.3 Development Prospect
Selected Charts

- Types of Diabetes
- Classification and Characteristics of Insulin Dosage Forms (by Technology)
- Classification and Typical Products of Insulin Dosage Forms (by Effective Time)
- Insulin Industry Chain
- Global Market Scale of Diabetes Drugs and Insulin Drugs, 2008-2010
- Classification of Global Diabetes Drugs, 2010
- R & D of Inhaled Insulin Dosage Form, 2006-2009
- Global Insulin Pump Market Scale, 2009-2016
- Recombinant Human Insulin Production Carrier and its Characteristics
- Global Number of Diabetes Patients, 2005-2009
- Global Theoretic Demand for Insulin API, 2009
- Top Three Countries by Number of Diabetes Patients, 2009
- Top Three Enterprises in Global Insulin Market, 2009
- Sales of Major Producers in Global Insulin Analog Market, 2009
- Drugs for the Immune Therapy of Type I Diabetes under Development, May 2010
- Glucagon-like Peptide 1 (GLP-1)-related Drugs
- Insulin Cell Transplantation Research Institutions and Progress, Dec. 2010
- Global Market Scale of the Drugs for the Treatment of Type I Diabetes, 2007-2017
- China’s Insulin Drug Market Scale, 2008-2009
- Purchase Prices and YoY Growth of Some Insulin Products of Typical Hospitals in 22 Cities of China, 2009
- Enterprises in China's Insulin Market by Market Share, Jan.-Sep. 2010
- Enterprises in China’s Insulin Analog Market by Market Share, 2008
- Current or Potential Insulin Producers in China, 2010
- Operating Gross Margin of Recombinant Human Insulin Products of Tonghua Dongbao, 2008-2010
Selected Charts

- Prices of Common Insulin Products in China, 2009-2010
- Insulin Included in the Health Insurance Directory of China, 2009
- Average Insulin Utilization of Diabetes Patients by Country, 2009
- Market Occupancy of China’s Insulin and Oral Hypoglycemic Drugs, 2007-2009
- China’s Export Value and Prices of Insulin and its Salts, 2008-2010
- China’s Export of Insulin and its Salts by Destination, Jan.-Nov. 2010
- China’s Import Value and Prices of Insulin and its Salts, 2008-2010
- China’s Import of Insulin and its Salts by Country of Origin, Jan.-Nov. 2010
- China’s Cumulative Export Value of Insulin-containing Drugs in Unfinished Dosage Form, Jan.-Nov. 2010
- China’s Export of Insulin-containing Drugs in Unfinished Dosage Form by Destination, Jan.-Nov. 2010
- China’s Export Value and Prices of Insulin-containing Drugs in Finished Dosage Form, 2008-2010
- China’s Export of Insulin-containing Drugs in Finished Dosage Form by Destination, Jan.-Nov. 2010
- China’s Import Value and Prices of Insulin-containing Drugs in Finished Dosage Form, 2008-2010
- China’s Import of Insulin-containing Drugs in Finished Dosage Form by Country of Origin, Jan.-Nov. 2010
- Operating Income of Tonghua Dongbao, 2008-2010
- Operating Income and Profit of Recombinant Human Insulin Products of Tonghua Dongbao, 2008-2010
- Sales Expenses and YoY Growth of Tonghua Dongbao, 2008-2010
- Development of Tonghua Dongbao, 2009-2010
- Hospital Procurement Amount of Beijing Gan & Lee Pharmaceutical, 2008-2009
- Total Operating Income and Operating Profit of Novo Nordisk, 2008-2010
- Main Businesses and Products of Novo Nordisk, H1 2010
- Operating Income and YoY Growth of Recombinant Human Insulin and Insulin Analog of Novo Nordisk, 2008-2010
- Novo Nordisk in China, 2009
- Sales Revenue of Novo Nordisk by Region, 2007-2009
- Development of Novo Nordisk, 2009-2011
• Major Products of Eli Lilly, 2009
• Total Operating Income and Profit of Eli Lilly, 2007-2010
• Operating Income of Eli Lilly by Division, 2009
• Operating Income of Humulin and Humalog of Eli Lilly, 2007-2010
• Eli Lilly in China, 2010
• Operating Income, Operating Expenses and Profit of Eli Lilly Suzhou Pharmaceutical, 2007-2008
• Development of Eli Lilly, 2008-2013
• Diabetes Products of Sanofi-Aventis, 2009
• Operating Income and Profit of Sanofi-Aventis, 2007-2010
• Operating Income of Insulin-related Products of Sanofi-Aventis, 2008-2010
• Operating Income of Insulin-related Products of Sanofi-Aventis by Region, H1 2010
• Sanofi-Aventis in China, 2010
• Plants of Sanofi-Aventis in China, 2010,
• Sanofi-Aventis’ Development in the Field of Insulin Products
• Profile of Jiangsu Wanbang Pharmaceuticals
• Insulin Products of Jiangsu Wanbang Pharmaceuticals, 2010
• Net Income of Jiangsu Wanbang Pharmaceuticals by Main Business, 2007-2010
• Unit Energy Consumption of Insulin Production of Jiangsu Wanbang Pharmaceuticals, 2008-2009
• Development of Jiangsu Wanbang Pharmaceuticals, 2009-2010
How to Buy

You can place your order in the following alternative ways:

1. Order online at www.researchinchina.com
2. Fax order sheet to us at fax number: +86 10 82601570
3. Email your order to: report@researchinchina.com
4. Phone us at +86 10 82600828/82600893

Choose type of format

- Hard copy...............1500 USD
- PDF (Single user license).........1400 USD
- PDF (Enterprisewide license).....2100 USD

※ Reports will be dispatched immediately once full payment has been received.
Payment may be made by wire transfer or credit card via Paypal.

Title | Format | Cost
---|---|---

| Party A: |
|---|---|---|
| Name: | | |
| Address: | | |
| Contact Person: | Tel | |
| E-mail: | | |

| Party B: |
|---|---|---|
| Name: Beijing Waterwood Technologies Co., Ltd (ResearchInChina) | | |
| Address: Room 1008, A2, Tower A, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080 | | |
| Contact Person: Liao Yan | Phone: 86-10-82600828 | |
| E-mail: report@researchinchina.com | Fax: 86-10-82601570 | |
| Bank details: Beneficial Name: Beijing Waterwood Technologies Co., Ltd Bank Name: Bank of Communications, Beijing Branch Bank Address: NO.1 jinxiyuan shijicheng,landianchang,Haidian District,Beijing Bank Account No #: 110060668012015061217 Routing No #: 332906 Bank SWIFT Code: COMMCNSHBJG | | |

Total | | |